Evaluation for secondary causes of headache: The role of blood and urine testing

Headache

Volumn 51, Issue 2, 2011, Pages 338-345

  Loder, Elizabeth ^a   Cardona, Luzma ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

headache; migraine; secondary headache; testing; workup

Indexed keywords

BLOOD ANALYSIS; CADASIL; DIAGNOSTIC PROCEDURE; EVALUATION; GIANT CELL ARTERITIS; HOMEOSTASIS; HUMAN; INFECTION; INTRACRANIAL HYPERTENSION; MELAS SYNDROME; PHYSICAL EXAMINATION; PRIMARY HEADACHE; PRIORITY JOURNAL; REVIEW; SECONDARY HEADACHE; URINALYSIS; VASCULAR DISEASE; WITHDRAWAL SYNDROME;

CADASIL; GIANT CELL ARTERITIS; HEADACHE; HEMATOLOGIC TESTS; HUMANS; MELAS SYNDROME; URINALYSIS; VASCULAR DISEASES;

EID: 79551593684     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01840.x     Document Type: Review

References (42)

1. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl. 1): 9-160.
2. Dodick DW,. Diagnosing headache: Clinical clues and clinical rules. Adv Stud Med. 2003; 3: 87-92.
3. James P, Di Paola J,. The application of genetics to inherited bleeding disorders. Haemophilia. 2010; 16 (Suppl. 5): 35-39.
4. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990; 33: 1122-1128.
5. Miller A, Green M, Robinson D,. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983; 286: 266.
6. Hayreh SS, Podhajsky PA, Raman R, Zimmerman B,. Giant cell arteritis: Validity and reliability of various diagnostic criteria. Am J Ophthalmol. 1997; 123: 285-296.
7. Parikh M, Miller NR, Lee AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology. 2006; 113: 1842-1845.
8. Costello F, Zimmerman MB, Podhajsky PA, Hayreh SS,. Role of thrombocytosis in diagnosis of giant cell arteritis and differentiation of arteritic from non-arteritic anterior ischemic optic neuropathy. Eur J Ophthalmol. 2004; 14: 245-257.
9. Markus HS, Martin RJ, Simpson MA, et al. Diagnostic strategies in CADASIL. Neurology. 2002; 59: 1134-1138.
10. Joutel A, Favrole P, Labauge P, et al. Skin biopsy immunostaining with a Notch3 monoclonal antibody for CADASIL diagnosis. Lancet. 2001; 358: 2049-2051.
11. Tikka S, Mykkanen K, Ruchoux MM, et al. Congruence between NOTCH3 mutations and GOM in 131 CADASIL patients. Brain. 2009; 132: 933-939.
12. Pantoni L, Pescini F, Nannucci S, et al. Comparison of clinical, familial, and MRI features of CADASIL and NOTCH3-negative patients. Neurology. 2010; 74: 57-63.
13. Testai FD, Gorelick PB,. Inherited metabolic disorders and stroke part 2: Homocystinuria, organic acidurias, and urea cycle disorders. Arch Neurol. 2010; 67: 148-153.
14. Rahman S, Poulton J, Marchington D, Suomalainen A,. Decrease of 3243 A->G mtDNA mutation from blood in MELAS syndrome: A longitudinal study. Am J Hum Genet. 2001; 68: 238-240.
15. Pyle A, Taylor RW, Durham SE, et al. Depletion of mitochondrial DNA in leucocytes harbouring the 3243A->G mtDNA mutation. J Med Genet. 2007; 44: 69-74.
16. Deventer K, Delbeke FT, Roels K, Van Eenoo P,. Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr. 2002; 16: 529-535.
17. Arndt PA, Kumpel BM,. Blood doping in athletes-detection of allogeneic blood transfusions by flow cytofluorometry. Am J Hematol. 2008; 83: 657-667.
18. Jenkinson DM, Harbert AJ,. Supplements and sports. Am Fam Physician. 2008; 78: 1039-1046.
19. Catlin DH, Fitch KD, Ljungqvist A,. Medicine and science in the fight against doping in sport. J Intern Med. 2008; 264: 99-114.
20. World Anti-Doping Agency Anti-Doping Laboratories; Available at: [accessed on 29 December 2010].
21. Dhungana S, Sharrack B, Woodroofe N,. Idiopathic intracranial hypertension. Acta Neurol Scand. 2010; 121: 71-82.
22. Hochberg MC,. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997; 40: 1725.
23. Galli M,. Clinical utility of laboratory tests used to identify antiphospholipid antibodies and to diagnose the antiphospholipid syndrome. Semin Thromb Hemost. 2008; 34: 329-334.
24. Warniment C, Tsang K, Galazka SS,. Lead poisoning in children. Am Fam Physician. 2010; 81: 751-757.
25. Dental amalgam: Update on safety concerns. ADA council on Scientific Affairs. J Am Dent Assoc. 1998; 129: 494-503.
26. Bailer J, Witthoft M, Paul C, Bayerl C, Rist F,. Evidence for overlap between idiopathic environmental intolerance and somatoform disorders. Psychosom Med. 2005; 67: 921-929.
27. Zimmer H, Ludwig H, Bader M, et al. Determination of mercury in blood, urine and saliva for the biological monitoring of an exposure from amalgam fillings in a group with self-reported adverse health effects. Int J Hyg Environ Health. 2002; 205: 205-211.
28. Baratz R. Steer clear of "compatibility testing." Available at: (Accessed 29 December 2010).
29. Nuttall KL,. Interpreting mercury in blood and urine of individual patients. Ann Clin Lab Sci. 2004; 34: 235-250.
30. Risher JF, Amler SN,. Mercury exposure: Evaluation and intervention the inappropriate use of chelating agents in the diagnosis and treatment of putative mercury poisoning. Neurotoxicology. 2005; 26: 691-699.
31. Hurley RA, Taber KH,. Acute and chronic Lyme disease: Controversies for neuropsychiatry. J Neuropsychiatry Clin Neurosci. 2008; 20: iv-6.
32. Pachner AR, Steiner I,. Lyme neuroborreliosis: Infection, immunity, and inflammation. Lancet Neurol. 2007; 6: 544-552.
33. Vanhems P, Allard R, Cooper DA, et al. Acute human immunodeficiency virus type 1 disease as a mononucleosis-like illness: Is the diagnosis too restrictive? Clin Infect Dis. 1997; 24: 965-970.
34. Kudva YC, Sawka AM, Young WF Jr,. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: The Mayo Clinic experience. J Clin Endocrinol Metab. 2003; 88: 4533-4539.
35. Sibai B, Dekker G, Kupferminc M,. Pre-eclampsia. Lancet. 2005; 365: 785-799.
36. Sawin CT, Castelli WP, Hershman JM, McNamara P, Bacharach P,. The aging thyroid. Thyroid deficiency in the Framingham Study. Arch Intern Med. 1985; 145: 1386-1388.
37. Allahabadia A, Razvi S, Abraham P, Franklyn J,. Diagnosis and treatment of primary hypothyroidism. BMJ. 2009; 338: b725.
38. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87: 489-499.
39. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: Scientific review and guidelines for diagnosis and management. JAMA. 2004; 291: 228-238.
40. Yamada M, Mori M,. Mechanisms related to the pathophysiology and management of central hypothyroidism. Nat Clin Pract Endocrinol Metab. 2008; 4: 683-694.
41. Deyo RA,. Cascade effects of medical technology. Annu Rev Public Health. 2002; 23: 23-44.
42. Hofer TP, Hayward RA,. Are bad outcomes from questionable clinical decisions preventable medical errors? A case of cascade iatrogenesis. Ann Intern Med. 2002; 137 (5 Part 1): 327-333.